Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.66 per share when it actually produced a loss of $0.54, delivering a surprise of 18.18%. Over the last four quarters, the company ha ...